11 posts on this topic, sorted most recent first.
Semaglutide is sold under four brand names with three different routes of administration and shifting region-by-region availability. Here's the complete index of Panya coverage, organized by what you're trying to figure out.
Three telehealth operators (Juniper, Pilot, Mosh) plus LillyDirect's direct path. TGA September 2025 advertising enforcement reset the marketing landscape. Brand-pharmacy supply only · Australia doesn't have a US-style compounded GLP-1 market. Per-month pricing, what each operator actually offers, who fits where.
A reader sent me a denial letter from her US insurer. They covered Wegovy. They didn't cover Mounjaro. Same patient, same diagnosis, same prescriber. The reason isn't medical. It's a contract that nobody mentions.
It's the most-asked question in the GLP-1 conversation and the answer most articles give is some version of 'tirzepatide loses more weight, choose tirzepatide if you can.' That's directionally true and practically incomplete. Here's the version that actually helps you decide.
MOH Circular 87/2024 hit its one-year anniversary in March; the in-person-consultation rule is now observable, not theoretical. Foundayo (orforglipron) HSA pathway tracking 12-18 months behind FDA. Oral Wegovy 25mg HSA filing the more imminent question. What changed for SG readers since the April buyer's guide.
What changed for UK GLP-1 access since the April 2026 buyer's guide. NHS QOF tirzepatide indicators went live April 1; Cohort 2 (BMI 35-39.9) starts June; oral Wegovy 25mg shipped at private pharmacies in January; Foundayo (orforglipron) MHRA pathway tracked. Private market still dominant. What to do today.
Bangkok is the regional anchor for legitimately-supplied tirzepatide and semaglutide in Southeast Asia. Flight matrices, clinic-relationship cadence, cold-chain transit, customs personal-use rules per origin country, and the four-versus-twelve-week supply math.
Weekly read on what's actually in stock at the Bangkok premium hospitals and mid-tier clinics, with price changes since last digest, regulatory movements that affect supply, and the picking question for this week. New format, weekly cadence, BKK-anchored. Issue 1.
HK Department of Health licenses Wegovy + Mounjaro for limited indications. Private clinic supply is steady but premium-priced. The 1h45 Bangkok flight is the cost-arbitrage many HK-resident expats end up using. What's actually licensed, per-clinic pricing, and the picking framework.
The Singapore GLP-1 clinic layer beyond the existing buyers guide. Per-clinic pricing for the four most-routable Singapore providers, MOH-licensed-product reality, the Wegovy-vs-Ozempic supply picture, and when the 2h20 Bangkok flight beats the local cost.
Side-by-side comparison of the three branded GLP-1 pens available in Bangkok in May 2026. Per-month USD pricing at premium hospitals and mid-tier clinics, supply state per medication, and the picking question once cost is on the table.